Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Comment by mediascan59on Jun 17, 2010 9:38am
481 Views
Post# 17197252

RE: Warrants??

RE: Warrants??Imo, if the company presents the facts according to the factual research that has been presented on this board, it will give credibility not only to the company, but to the drug as a viable contender towards the solution to treat strokes and possibly MS and TBI, and would immediately restore the true value of this play and open a door for those with warrants to be exercised.
It appears that everything that we have read since May 26, points to the fact that this is a viable solution and stating so with documentation will allow us to go forward once again.

Mediascan
Bullboard Posts